RE-BVS – Piemonte Repository

Sfoglia per AUTORE
DOORDUIJN J
Collezione AOU Alessandria

Items : 5

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network. in Lancet (London, England) / Lancet. 2026 May 16;407(10542):1953-1967. doi: 10.1016/S0140-6736(26)00362-4.

2026
AOU Alessandria

Herhaus P; Wirths S; Meerten TV; Heß G; Jachimowicz RD; Kerkhoff A; Stilgenbauer S; Jiang L; Leppä S; da Silva MG; Shpilberg O; Vergote VKJ; Trneny M; Riise J; Mey U; Hutchings M; Walewski J; Jerkeman M; Giné E; Doorduijn J; Dreyling M; Hoster E; Ladetto M; Tix T; Unterhalt M; Schmidt C; Klapper W; Pott C; Stefani PM; et alii...

Marked survival gains in patients ? 65 years with advanced-stage mantle cell lymphoma: a pooled analysis of six randomized phase III trials, 1996-2020. in Haematologica / Haematologica. 2026 May 1;111(5):1694-1704. doi: 10.3324/haematol.2025.288929. Epub 2025 Oct 30.

2026
AOU Alessandria

Jiang L; Ladetto M; Hermine O; Kluin-Nelemans JC; Walewski J; Doorduijn J; Vergote V; Giné E; Jerkeman M; Hutchings M; Trneny M; Mey U; Riise J; Shpilberg O; Da Silva MG; Ribrag V; Schmidt C; Klapper W; Unterhalt M; Dreyling M; Hoster E;

Rituximab Maintenance Added to Ibrutinib-Containing Therapy in Younger, Untreated Patients With Mantle Cell Lymphoma: Results From the TRIANGLE Trial. in Journal of clinical oncology : official journal of the American Society of Clinical Oncology / J Clin Oncol. 2026 Jul 14:JCO2600705. doi: 10.1200/JCO-26-00705.

2026
AOU Alessandria

Ladetto M; Gutmair K; Tavarozzi R; Pawlikowski A; Schomaker M; Doorduijn J; Giné E; Jerkeman M; Walewski J; Hutchings M; Mey U; Riise J; Trneny M; Vergote VKJ; Horowitz NA; Gomes da Silva M; Leppä S; Jiang L; Stilgenbauer S; Kerkhoff A; Jachimowicz RD; Heß G; van Meerten T; Wirths S; Herhaus P; Novak U; Dierlamm J; Hänel M; Hanoun C; et alii...

Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial. in Leukemia / Leukemia. 2026 Jan;40(1):95-105. doi: 10.1038/s41375-025-02787-0. Epub 2025 Nov 3.

2026
AOU Alessandria

Ladetto M; Brüggemann M; Baldus CD; Giné E; Visco C; Gameiro P; Doorduijn J; da Silva MG; Medina Herrera A; van der Velden VHJ; Homburg CHE; Sanz RG; Verhagen OJHM; Laqua A; Alessandria B; Ferrero S; Genuardi E; Khouja M; Schmidt C; Dreyling M; Jiang L; Hoster E; Darzentas N; Pal K; Chitadze G; Stewart JP; Gonzalez D; Pott C;

Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. in Lancet (London, England) / Lancet. 2024 May 25;403(10441):2293-2306. doi: 10.1016/S0140-6736(24)00184-3. Epub 2024 May 2.

2024
AOU Alessandria

Dreyling M; Doorduijn J; Giné E; Jerkeman M; Walewski J; Hutchings M; Mey U; Riise J; Trneny M; Vergote V; Shpilberg O; Gomes da Silva M; Leppä S; Jiang L; Stilgenbauer S; Kerkhoff A; Jachimowicz RD; Celli M; Hess G; Arcaini L; Visco C; van Meerten T; Wirths S; Zinzani PL; Novak U; Herhaus P; Benedetti F; Sonnevi K; Hanoun C; et alii...